Needham Reiterates Buy on Clearside Biomedical, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Clearside Biomedical (NASDAQ:CLSD) and maintained a $4 price target.
May 13, 2024 | 9:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger reiterates a Buy rating on Clearside Biomedical, with a maintained price target of $4.
The reiteration of a Buy rating and maintenance of a $4 price target by a reputable analyst could positively influence investor sentiment towards CLSD, potentially driving its stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100